Prosecution Insights
Last updated: April 19, 2026
Application No. 17/290,629

BIO-PESTICIDE OIL FORMULATION

Non-Final OA §112
Filed
Apr 30, 2021
Examiner
CHEN, CATHERYNE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Indian Oil Corporation Limited
OA Round
3 (Non-Final)
37%
Grant Probability
At Risk
3-4
OA Rounds
4y 7m
To Grant
55%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allow Rate
284 granted / 769 resolved
-23.1% vs TC avg
Strong +18% interview lift
Without
With
+18.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 7m
Avg Prosecution
48 currently pending
Career history
817
Total Applications
across all art units

Statute-Specific Performance

§101
13.5%
-26.5% vs TC avg
§103
40.2%
+0.2% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 769 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on Aug. 22, 2025 has been entered. Claims 1-11 are pending and examined on the merits. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Any rejection not reiterated below are hereby withdrawn. Election/Restrictions Applicant’s election without traverse of glycerine, clear composition, polysaccharide in the reply filed on March 22, 2024 is acknowledged. Information Disclosure Statement The information disclosure statement (IDS) submitted on 4/30/21 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Response to Amendment Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1, 6-8, and 10 recite the limitation "(B40035-H-70 LOBS GROUP 2)" in the claims. Is the "(B40035-H-70 LOBS GROUP 2)" part of the claim? Why are there parenthese? If it is a trademark, the term is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of the 35 U.S.C. 112, second paragraph. Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe an agro oil and, accordingly, the identification/description is indefinite. Claim 8 (d)(e)(f), “the suspension obtained in preceding step” is indefinite because there is insufficient antecedent basis for this limitation in the claim. Is the “suspension” referring to step (c)? Is preceding step in (e) referring to step (d)? The “preceding step” can be any preceding step in Claim 8. Please clarify by referring the each step alphabetically. Claims dependent on a rejected claim are rejected for failing to cure the indefiniteness. Conclusion No claim is allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERYNE CHEN whose telephone number is (571)272-9947. The examiner can normally be reached on Monday-Friday 9-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice . If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand U Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Catheryne Chen Examiner Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Apr 30, 2021
Application Filed
Jun 27, 2024
Non-Final Rejection — §112
Jan 13, 2025
Response Filed
May 16, 2025
Final Rejection — §112
Jul 22, 2025
Response after Non-Final Action
Aug 22, 2025
Request for Continued Examination
Aug 25, 2025
Response after Non-Final Action
Feb 20, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589184
CLINICAL DRESSING LOADED WITH COFFEE EXTRACT
2y 5m to grant Granted Mar 31, 2026
Patent 12569424
STABLE VITAMIN C COMPOSITIONS
2y 5m to grant Granted Mar 10, 2026
Patent 12551521
COMPOSITIONS INCLUDING PINE BARK EXTRACT, BERRYFRUIT EXTRACT AND A SOURCE OF L-THEANINE AND USES THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12551520
MAQUI BERRY EXTRACTS FOR TREATMENT OF SKIN DISEASES
2y 5m to grant Granted Feb 17, 2026
Patent 12544352
DIAPER CREAM
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
37%
Grant Probability
55%
With Interview (+18.4%)
4y 7m
Median Time to Grant
High
PTA Risk
Based on 769 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month